Coherus Biosciences (NASDAQ:CHRS) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Monday, ValuEngine reports.

Several other brokerages have also recently commented on CHRS. SunTrust Banks assumed coverage on shares of Coherus Biosciences in a research report on Friday, April 17th. They issued a “buy” rating and a $26.00 price target on the stock. Maxim Group assumed coverage on shares of Coherus Biosciences in a research note on Saturday, May 9th. They set a “buy” rating and a $27.00 target price for the company. BidaskClub lowered shares of Coherus Biosciences from a “sell” rating to a “strong sell” rating in a research report on Tuesday, June 16th. TheStreet upgraded Coherus Biosciences from a “d+” rating to a “c-” rating in a research report on Friday, March 20th. Finally, Zacks Investment Research raised Coherus Biosciences from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research note on Monday. Two investment analysts have rated the stock with a sell rating and eight have assigned a buy rating to the stock. Coherus Biosciences has an average rating of “Buy” and an average price target of $30.88.

Shares of NASDAQ:CHRS opened at $17.33 on Monday. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of 8.84 and a beta of 2.05. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.32 and a quick ratio of 3.18. Coherus Biosciences has a 12 month low of $10.86 and a 12 month high of $23.91. The stock’s 50 day moving average price is $17.46 and its 200 day moving average price is $17.77.

Coherus Biosciences (NASDAQ:CHRS) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.10. The company had revenue of $116.18 million for the quarter, compared to analysts’ expectations of $116.25 million. Coherus Biosciences had a return on equity of 190.82% and a net margin of 33.42%. On average, sell-side analysts expect that Coherus Biosciences will post 1.31 EPS for the current year.

In other news, Director Mary T. Szela sold 54,997 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $17.58, for a total value of $966,847.26. Following the completion of the sale, the director now owns 14,997 shares of the company’s stock, valued at $263,647.26. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mats Wahlstrom sold 200,000 shares of Coherus Biosciences stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $17.15, for a total value of $3,430,000.00. The disclosure for this sale can be found here. Insiders sold a total of 268,925 shares of company stock valued at $4,627,867 in the last ninety days. Company insiders own 15.86% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Victory Capital Management Inc. increased its holdings in shares of Coherus Biosciences by 5.8% in the 4th quarter. Victory Capital Management Inc. now owns 10,438 shares of the biotechnology company’s stock valued at $188,000 after purchasing an additional 575 shares during the period. Principal Financial Group Inc. grew its position in Coherus Biosciences by 1.4% during the first quarter. Principal Financial Group Inc. now owns 47,157 shares of the biotechnology company’s stock valued at $765,000 after purchasing an additional 629 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Coherus Biosciences by 27.3% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,617 shares of the biotechnology company’s stock valued at $75,000 after buying an additional 990 shares during the period. Private Capital Group LLC increased its stake in Coherus Biosciences by 244.7% in the 1st quarter. Private Capital Group LLC now owns 2,382 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 1,691 shares during the period. Finally, Jane Street Group LLC lifted its position in Coherus Biosciences by 15.7% in the 4th quarter. Jane Street Group LLC now owns 12,671 shares of the biotechnology company’s stock worth $228,000 after buying an additional 1,721 shares in the last quarter.

About Coherus Biosciences

Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.

Featured Article: Producer Price Index (PPI)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.